1
|
Saini I, Joshi J, Kaur S. Leishmania vaccine development: A comprehensive review. Cell Immunol 2024; 399-400:104826. [PMID: 38669897 DOI: 10.1016/j.cellimm.2024.104826] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2024] [Revised: 04/18/2024] [Accepted: 04/21/2024] [Indexed: 04/28/2024]
Abstract
Infectious diseases like leishmaniasis, malaria, HIV, tuberculosis, leprosy and filariasis are responsible for an immense burden on public health systems. Among these, leishmaniasis is under the category I diseases as it is selected by WHO (World Health Organization) on the ground of diversity and complexity. High cost, resistance and toxic effects of Leishmania traditional drugs entail identification and development of therapeutic alternative. Since the natural infection elicits robust immunity, consistence efforts are going on to develop a successful vaccine. Clinical trials have been conducted on vaccines like Leish-F1, F2, and F3 formulated using specific Leishmania antigen epitopes. Current strategies utilize individual or combined antigens from the parasite or its insect vector's salivary gland extract, with or without adjuvant formulation for enhanced efficacy. Promising animal data supports multiple vaccine candidates (Lmcen-/-, LmexCen-/-), with some already in or heading for clinical trials. The crucial challenge in Leishmania vaccine development is to translate the research knowledge into affordable and accessible control tools that refines the outcome for those who are susceptible to infection. This review focuses on recent findings in Leishmania vaccines and highlights difficulties facing vaccine development and implementation.
Collapse
Affiliation(s)
- Isha Saini
- Parasitology Laboratory, Department of Zoology, Panjab University, Chandigarh, India
| | - Jyoti Joshi
- Goswami Ganesh Dutta Sanatan Dharma College, Sector-32C, Chandigarh, India
| | - Sukhbir Kaur
- Parasitology Laboratory, Department of Zoology, Panjab University, Chandigarh, India.
| |
Collapse
|
2
|
Flau-A, a naphthoquinone derivative, is a promising therapeutic candidate against visceral leishmaniasis: A preliminary study. Exp Parasitol 2021; 233:108205. [PMID: 34968460 DOI: 10.1016/j.exppara.2021.108205] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2021] [Revised: 11/30/2021] [Accepted: 12/25/2021] [Indexed: 11/21/2022]
Abstract
Visceral leishmaniasis (VL) is a neglected tropical disease found in tropical and subtropical regions in the world. The therapeutics used for the treatment against disease presents problems, mainly related to drug toxicity, route of administration, high cost and/or by emergence of resistant strains. In this context, the search for alternative antileishmanial candidates is desirable. Recently, a naphthoquinone derivative namely 2-(2,3,4-tri-O-acetyl-6-deoxy-β-L-galactopyranosyloxy)-1,4-naphthoquinone or Flau-A showed an effective in vitro biological action against Leishmania infantum. In the present study, the efficacy of this naphthoquinone derivative was evaluated in an in vivo infection model. BALB/c mice (n = 12 per group) were infected and later received saline or were treated with empty micelles (B/Mic), free Flau-A or it incorporated in Poloxamer 407-based micelles (Flau-A/Mic). The products were administered subcutaneously in the infected animals, which were then euthanized one (n = 6 per group) and 15 (n = 6 per group) days post-therapy, when immunological and parasitological evaluations were performed. Results showed that animals treated with Flau-A or Flau-A/Mic produced significantly higher levels of antileishmanial IFN-γ, IL-12, TNF-α, GM-CSF, nitrite and IgG2a isotype antibody, when compared to data found in the control (saline and B/Mic) groups; which showed significantly higher levels of parasite-specific IL-4, IL-10 and IgG1 antibody. In addition, animals receiving free Flau-A or Flau-A/Mic presented also significant reductions in the parasite load in their spleens, livers, bone marrows and draining lymph nodes, when compared to the controls. A low hepatic and renal toxicity was also found. Overall, Flau-A/Mic showed better immunological and parasitological results, when compared to the use of free molecule. In conclusion, preliminary data suggest that this composition could be considered in future studies as promising therapeutic candidate against VL.
Collapse
|
3
|
Barbosa de Castro R, Badaró de Moraes JV, Costa Bressan G, de Souza Vasconcellos R, Silva-Júnior A, Lopes Rangel Fietto J. Antigens and their diagnostic performance for Canine Visceral Leishmaniasis: A critical review. Vet Parasitol 2021; 301:109638. [PMID: 34920304 DOI: 10.1016/j.vetpar.2021.109638] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2021] [Revised: 11/22/2021] [Accepted: 12/09/2021] [Indexed: 01/27/2023]
Abstract
Canine visceral leishmaniasis (CVL) is the most aggressive and lethal form of leishmaniasis manifesting in dogs and represents a major public health concern. Although there are sufficiently sensitive molecular tools for CVL diagnosis, they are not accessible at the main points of disease dissemination, in which context serodiagnosis has been used as an alternative tool on the epidemiological control. As an attempt to develop more accurate immunodiagnostic assays, many antigens have been tested over the years, on different platforms. This review aimed to access studies reporting new antigens that can be applied for CVL serodiagnosis. Articles published from January of 2016 to March of 2021 were retrieved from Google Scholar, Science Direct, and PubMed, using "Canine Visceral Leishmaniasis" and "Serodiagnosis" as keywords. In total, 1527 articles were identified, of which 42 were selected based on exclusion factors. Sensitivity, specificity, sample size, and sample quality data were extracted by manual curation and analyzed. Of the selected articles, 26 contemplated ELISA, which enabled a more thorough comparison and a critical review of these studies. Soluble Leishmania Antigens (SLA) and the A2 protein were used as controls in 53.8 and 46.15 % of these articles, respectively, and were evaluated separately; their frequent use was questioned. Subsequently, articles that evaluated other assay platforms, such as immunochromatography, immunosensors, and others, were also reported and evaluated. Finally, data relative to validation studies of commercial kits were briefly discussed. Our results show that there are several antigens with great potential for the development of accurate diagnostic tools, but further testing is required. The critical analysis also brings insights that can be useful for more assertive diagnostic development of more robust tools for CVL serodiagnosis.
Collapse
Affiliation(s)
- Raissa Barbosa de Castro
- Departamento de Bioquímica e Biologia Molecular, Universidade Federal de Viçosa, Av. P. H. Rolfs, s/n, Campus Universitário, CEP: 36570-000 Viçosa, MG, Brazil
| | - João Victor Badaró de Moraes
- Departamento de Biologia Geral, Av. P. H. Rolfs, s/n, Campus Universitário, CEP: 36570-000, Universidade Federal de Viçosa, Viçosa, MG, Brazil
| | - Gustavo Costa Bressan
- Departamento de Bioquímica e Biologia Molecular, Universidade Federal de Viçosa, Av. P. H. Rolfs, s/n, Campus Universitário, CEP: 36570-000 Viçosa, MG, Brazil
| | - Raphael de Souza Vasconcellos
- Departamento de Bioquímica e Biologia Molecular, Universidade Federal de Viçosa, Av. P. H. Rolfs, s/n, Campus Universitário, CEP: 36570-000 Viçosa, MG, Brazil
| | - Abelardo Silva-Júnior
- Departamento de Veterinária, Av. P. H. Rolfs, s/n, Campus Universitário, CEP: 36570-000, Universidade Federal de Viçosa, Viçosa, MG, Brazil
| | - Juliana Lopes Rangel Fietto
- Departamento de Bioquímica e Biologia Molecular, Universidade Federal de Viçosa, Av. P. H. Rolfs, s/n, Campus Universitário, CEP: 36570-000 Viçosa, MG, Brazil.
| |
Collapse
|
4
|
Evaluation of Cysteine Protease C of Leishmania donovani in Comparison with Glycoprotein 63 and Elongation Factor 1α for Diagnosis of Human Visceral Leishmaniasis and for Posttreatment Follow-Up Response. J Clin Microbiol 2020; 58:JCM.00213-20. [PMID: 32848039 DOI: 10.1128/jcm.00213-20] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2020] [Accepted: 07/30/2020] [Indexed: 12/21/2022] Open
Abstract
Visceral leishmaniasis (VL) is a threat in many developing countries. Much effort has been put to eliminating this disease, for which serodiagnosis remains the mainstay for VL control programs. New and improved antigens as diagnostic candidates are required, though, as the available antigens fail to demonstrate equal optimum performance in all areas of endemicity. Moreover, these diagnoses are dependent on invasive serum sampling. In the current study, we cloned and expressed Leishmania donovani cysteine protease C (CPC) and evaluated its diagnostic and test-of-cure possibilities by detecting the antibody levels in human serum and urine through ELISA and immunoblot assays. Two immunodominant antigens, recombinant glycoprotein 63 (GP63) and elongation factor 1α (EF1α), identified earlier by our group, were also assessed by employing human serum and urine samples. Of these three antigens in ELISAs, CPC demonstrated the highest sensitivities of 98.15% and 96% positive testing in serum and urine of VL patients, respectively. Moreover, CPC yielded 100% specificity with serum and urine of nonendemic healthy controls compared to GP63 and EF1α. Urine samples were found to be more specific than serum for distinguishing endemic healthy controls and other diseases by means of all three antigens. In all cases, CPC gave the most promising results. Unlike serum, urine tests demonstrated a significant decrease in antibody levels for CPC, GP63, and EF1α after 6 months of treatment. The diagnostic and test-of-cure performances of CPC in the immunoblot assay were found to be better than those of GP63 and EF1α. In conclusion, CPC, followed by GP63 and EF1α, may be utilized as candidates for diagnosis of VL and to assess treatment response.
Collapse
|
5
|
Evaluation of the protective efficacy of a Leishmania protein associated with distinct adjuvants against visceral leishmaniasis and in vitro immunogenicity in human cells. Parasitol Res 2020; 119:2609-2622. [PMID: 32535734 DOI: 10.1007/s00436-020-06752-x] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2019] [Accepted: 06/02/2020] [Indexed: 10/24/2022]
Abstract
The treatment against visceral leishmaniasis (VL) presents problems, mainly related to the toxicity and/or high cost of the drugs. In this context, a prophylactic vaccination is urgently required. In the present study, a Leishmania protein called LiHyE, which was suggested recently as an antigenic marker for canine and human VL, was evaluated regarding its immunogenicity and protective efficacy in BALB/c mice against Leishmania infantum infection. In addition, the protein was used to stimulate peripheral blood mononuclear cells (PBMCs) from VL patients before and after treatment, as well as from healthy subjects. Vaccination results showed that the recombinant (rLiHyE) protein associated with liposome or saponin induced effective protection in the mice, since significant reductions in the parasite load in spleen, liver, draining lymph nodes, and bone marrow were found. The parasitological protection was associated with Th1-type cell response, since high IFN-γ, IL-12, and GM-CSF levels, in addition to low IL-4 and IL-10 production, were found. Liposome induced a better parasitological and immunological protection than did saponin. Experiments using PBMCs showed rLiHyE-stimulated lymphoproliferation in treated patients' and healthy subjects' cells, as well as high IFN-γ levels in the cell supernatant. In conclusion, rLiHyE could be considered for future studies as a vaccine candidate against VL.
Collapse
|
6
|
Liposomal Formulation of ChimeraT, a Multiple T-Cell Epitope-Containing Recombinant Protein, Is a Candidate Vaccine for Human Visceral Leishmaniasis. Vaccines (Basel) 2020; 8:vaccines8020289. [PMID: 32526867 PMCID: PMC7349940 DOI: 10.3390/vaccines8020289] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2020] [Revised: 06/01/2020] [Accepted: 06/06/2020] [Indexed: 02/07/2023] Open
Abstract
Background: Leishmaniases are neglected diseases caused by infection with Leishmania parasites and there are no human vaccines in use routinely. The purpose of this study was to examine the immunogenicity of ChimeraT, a novel synthetic recombinant vaccine against visceral leishmaniasis (VL), incorporated into a human-compatible liposome formulation. Methods: BALB/c mice were immunized subcutaneously with ChimeraT/liposome vaccine, ChimeraT/saponin adjuvant, or ChimeraT/saline and immune responses examined in vitro and in vivo. Results: Immunization with the ChimeraT/liposome formulation induced a polarized Th1-type response and significant protection against L. infantum infection. ChimeraT/liposome vaccine stimulated significantly high levels of interferon (IFN)-γ, interleukin (IL)-12, and granulocyte macrophage-colony stimulating factor (GM-CSF) cytokines by both CD4 and CD8 T-cells, with correspondingly lower levels of IL-4 and IL-10 cytokines. Induced antibodies were predominantly IgG2a isotype, and homologous antigen-stimulated spleen cells produced significant nitrite as a proxy for nitric oxide (NO). Furthermore, we examined a small number of treated VL patients and found higher levels of circulating anti-ChimeraT protein IgG2 antibodies, compared to IgG1 levels. Conclusions: Overall, the liposomal formulation of ChimeraT induced a protective Th1-type immune response and thus could be considered in future studies as a vaccine candidate against human VL.
Collapse
|
7
|
Ramírez L, de Moura LD, Mateus NLF, de Moraes MH, do Nascimento LFM, de Jesus Melo N, Taketa LB, Catecati T, Huete SG, Penichet K, Piranda EM, de Oliveira AG, Steindel M, Barral-Netto M, do Socorro Pires e Cruz M, Barral A, Soto M. Improving the serodiagnosis of canine Leishmania infantum infection in geographical areas of Brazil with different disease prevalence. Parasite Epidemiol Control 2020; 8:e00126. [PMID: 31832561 PMCID: PMC6890974 DOI: 10.1016/j.parepi.2019.e00126] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2019] [Accepted: 11/19/2019] [Indexed: 01/31/2023] Open
Abstract
Serodiagnosis of Leishmania infantum infection in dogs relies on the detection of antibodies against leishmanial crude extracts or parasitic defined antigens. The expansion of canine leishmaniasis from geographical areas of Brazil in which the infection is endemic to regions in which the disease is emerging is occurring. This fact makes necessary the analysis of the serodiagnostic capabilities of different leishmanial preparations in distinct geographical locations. In this article sera from dogs infected with Leishmania and showing the clinical form of the disease, were collected in three distinct Brazilian States and were tested against soluble leishmanial antigens or seven parasite individual antigens produced as recombinant proteins. We show that the recognition of soluble leishmanial antigens by sera from these animals was influenced by the geographical location of the infected dogs. Efficacy of the diagnosis based on this crude parasite preparation was higher in newly endemic regions when compared with areas of high disease endemicity. We also show that the use of three of the recombinant proteins, namely parasite surface kinetoplastid membrane protein of 11 kDa (KMP-11), and two members of the P protein family (P2a and P0), can improve the degree of sensitivity without adversely affecting the specificity of the diagnostic assays for canine leishmaniasis, independently of the geographical area of residence. In addition, sera from dogs clinically healthy but infected were also assayed with some of the antigen preparations. We demonstrate that the use of these proteins can help to the serodiagnosis of Leishmania infected animals with subclinical infections. Finally, we propose a diagnostic protocol using a combination of KMP-11, P2a y P0, together with total leishmanial extracts.
Collapse
Key Words
- Antibodies
- BB, blocking buffer
- CanL, Canine visceral leishmaniasis
- Canine leishmaniasis
- EDCB, ELISA denaturant coating buffer
- ELISA, enzyme-linked immunosorbent assay
- HSP, Heat shock protein
- KMP-11, Kinetoplastid-membrane protein of 11 kDa
- LR, Likelihood ratio
- Leishmania
- MS, Mato Grosso do Sul State (Brazil)
- PBS, phosphate saline buffer
- PI, Piaui State (Brazil)
- ROC, Receiver Operating Characteristic
- RR, Relative reactivity
- RT, Room temperature
- Recombinant proteins
- SC, Santa Catarina State (Brazil)
- SLA, Soluble leishmanial antigen
- Serodiagnosis
- VL, Visceral leishmaniosis
- WB, Washing buffer
Collapse
Affiliation(s)
- Laura Ramírez
- Centro de Biología Molecular Severo Ochoa (CBMSO), Departamento de Biología Molecular, Facultad de Ciencias, CSIC-UAM, Universidad Autónoma de Madrid, 28049 Madrid, Spain
| | - Luana Dias de Moura
- Centro de Ciências Agrárias, Universidade Federal do Piaui (UFPI), Teresina, 64049-550 PI, Brazil
| | - Natalia Lopes Fontoura Mateus
- Laboratório de Parasitologia, Centro de Ciências Biológicas e da Saúde, Universidade Federal de Mato Grosso do Sul (UFMS), Cidade Universitária, s/n, Campo Grande 79070-900 MS, Brazil
| | - Milene Hoehr de Moraes
- Departamento de Microbiologia, Imunologia e Parasitologia, Universidade Federal de Santa Catarina (UFSC), Florianópolis 88040-900 SC, Brazil
| | | | - Nailson de Jesus Melo
- Centro de Ciências Agrárias, Universidade Federal do Piaui (UFPI), Teresina, 64049-550 PI, Brazil
| | - Lucas Bezerra Taketa
- Laboratório de Parasitologia, Centro de Ciências Biológicas e da Saúde, Universidade Federal de Mato Grosso do Sul (UFMS), Cidade Universitária, s/n, Campo Grande 79070-900 MS, Brazil
| | - Tatiana Catecati
- Departamento de Microbiologia, Imunologia e Parasitologia, Universidade Federal de Santa Catarina (UFSC), Florianópolis 88040-900 SC, Brazil
| | - Samuel G. Huete
- Centro de Biología Molecular Severo Ochoa (CBMSO), Departamento de Biología Molecular, Facultad de Ciencias, CSIC-UAM, Universidad Autónoma de Madrid, 28049 Madrid, Spain
| | - Karla Penichet
- Centro de Biología Molecular Severo Ochoa (CBMSO), Departamento de Biología Molecular, Facultad de Ciencias, CSIC-UAM, Universidad Autónoma de Madrid, 28049 Madrid, Spain
| | - Eliane Mattos Piranda
- Laboratório de Parasitologia, Centro de Ciências Biológicas e da Saúde, Universidade Federal de Mato Grosso do Sul (UFMS), Cidade Universitária, s/n, Campo Grande 79070-900 MS, Brazil
| | - Alessandra Gutierrez de Oliveira
- Laboratório de Parasitologia, Centro de Ciências Biológicas e da Saúde, Universidade Federal de Mato Grosso do Sul (UFMS), Cidade Universitária, s/n, Campo Grande 79070-900 MS, Brazil
| | - Mario Steindel
- Departamento de Microbiologia, Imunologia e Parasitologia, Universidade Federal de Santa Catarina (UFSC), Florianópolis 88040-900 SC, Brazil
| | - Manoel Barral-Netto
- Centro de Pesquisas Gonçalo Moniz (Fundação Oswaldo Cruz- FIOCRUZ). Waldemar Falcão, 121, Salvador 40296-710 BA, Brazil
| | | | - Aldina Barral
- Centro de Pesquisas Gonçalo Moniz (Fundação Oswaldo Cruz- FIOCRUZ). Waldemar Falcão, 121, Salvador 40296-710 BA, Brazil
| | - Manuel Soto
- Centro de Biología Molecular Severo Ochoa (CBMSO), Departamento de Biología Molecular, Facultad de Ciencias, CSIC-UAM, Universidad Autónoma de Madrid, 28049 Madrid, Spain
| |
Collapse
|
8
|
Martínez-Rodrigo A, S. Dias D, Ribeiro PAF, Roatt BM, Mas A, Carrión J, Coelho EAF, Domínguez-Bernal G. Immunization with the HisAK70 DNA Vaccine Induces Resistance against Leishmania Amazonensis Infection in BALB/c Mice. Vaccines (Basel) 2019; 7:vaccines7040183. [PMID: 31739549 PMCID: PMC6963319 DOI: 10.3390/vaccines7040183] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2019] [Revised: 11/11/2019] [Accepted: 11/13/2019] [Indexed: 12/04/2022] Open
Abstract
Leishmania amazonensis is the aetiological agent of a broad spectrum of leishmaniosis in South America. It can cause not only numerous cases of cutaneous leishmaniosis but also diffuse cutaneous leishmaniosis. Considering the diversity of parasite species causing different forms of the disease that coexist in the same region, it is desirable to develop a vaccine capable of eliciting cross-protection. We have previously described the use of HisAK70 DNA vaccine for immunization of mice to assess the induction of a resistant phenotype against Leishmania major and infantum infections. In this study, we extended its application in the murine model of infection by using L. amazonensis promastigotes. Our data revealed that 14 weeks post-infection, HisAK70-vaccinated mice showed key biomarkers of protection, such as higher iNOS/arginase activity, IFN-γ/IL-10, IFN-γ/IL-4, and GM-CSF/IL-10 ratios, in addition to an IgG2a-type response when compared to the control group. These findings correlated with the presentation of lower footpad swelling and parasite burdens in the immunized compared to the control mice. Overall, this study suggests that immunization with HisAK70 may be considered a suitable tool to combat leishmaniosis as it is able to induce a potent cellular immune response, which allows to control the infection caused by L. amazonensis.
Collapse
Affiliation(s)
- Abel Martínez-Rodrigo
- Departamento de Sanidad Animal, Facultad de Veterinaria, Universidad Complutense Madrid, INMIVET, 28040 Madrid, Spain; (A.M.-R.); (A.M.); (J.C.)
| | - Daniel S. Dias
- Programa de Pós-Graduação em Ciências da Saúde: Infectologia e Medicina Tropical, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte 30130-100, Minas Gerais, Brazil; (D.S.D.); (P.A.F.R.); (E.A.F.C.)
| | - Patrícia A. F. Ribeiro
- Programa de Pós-Graduação em Ciências da Saúde: Infectologia e Medicina Tropical, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte 30130-100, Minas Gerais, Brazil; (D.S.D.); (P.A.F.R.); (E.A.F.C.)
| | - Bruno M. Roatt
- Laboratório de Imunopatologia, Núcleo de Pesquisas em Ciências Biológicas, Universidade Federal de Ouro Preto, Ouro Preto 35400-000, Minas Gerais, Brazil;
| | - Alicia Mas
- Departamento de Sanidad Animal, Facultad de Veterinaria, Universidad Complutense Madrid, INMIVET, 28040 Madrid, Spain; (A.M.-R.); (A.M.); (J.C.)
| | - Javier Carrión
- Departamento de Sanidad Animal, Facultad de Veterinaria, Universidad Complutense Madrid, INMIVET, 28040 Madrid, Spain; (A.M.-R.); (A.M.); (J.C.)
| | - Eduardo A. F. Coelho
- Programa de Pós-Graduação em Ciências da Saúde: Infectologia e Medicina Tropical, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte 30130-100, Minas Gerais, Brazil; (D.S.D.); (P.A.F.R.); (E.A.F.C.)
- Departamento de Patologia Clínica, COLTEC, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, Minas Gerais, Brazil
| | - Gustavo Domínguez-Bernal
- Departamento de Sanidad Animal, Facultad de Veterinaria, Universidad Complutense Madrid, INMIVET, 28040 Madrid, Spain; (A.M.-R.); (A.M.); (J.C.)
- Correspondence: ; Tel.: +34-913943712
| |
Collapse
|
9
|
Screening diagnostic candidates from Leishmania infantum proteins for human visceral leishmaniasis using an immunoproteomics approach. Parasitology 2019; 146:1467-1476. [PMID: 31142384 DOI: 10.1017/s0031182019000714] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
There is no suitable vaccine against human visceral leishmaniasis (VL) and available drugs are toxic and/or present high cost. In this context, diagnostic tools should be improved for clinical management and epidemiological evaluation of disease. However, the variable sensitivity and/or specificity of the used antigens are limitations, showing the necessity to identify new molecules to be tested in a more sensitive and specific serology. In the present study, an immunoproteomics approach was performed in Leishmania infantum promastigotes and amastigotes employing sera samples from VL patients. Aiming to avoid undesired cross-reactivity in the serological assays, sera from Chagas disease patients and healthy subjects living in the endemic region of disease were also used in immunoblottings. The most reactive spots for VL samples were selected, and 29 and 21 proteins were identified in the promastigote and amastigote extracts, respectively. Two of them, endonuclease III and GTP-binding protein, were cloned, expressed, purified and tested in ELISA experiments against a large serological panel, and results showed high sensitivity and specificity values for the diagnosis of disease. In conclusion, the identified proteins could be considered in future studies as candidate antigens for the serodiagnosis of human VL.
Collapse
|
10
|
Ratnapriya S, Keerti, Sahasrabuddhe AA, Dube A. Visceral leishmaniasis: An overview of vaccine adjuvants and their applications. Vaccine 2019; 37:3505-3519. [PMID: 31103364 DOI: 10.1016/j.vaccine.2019.04.092] [Citation(s) in RCA: 30] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2018] [Revised: 03/08/2019] [Accepted: 04/30/2019] [Indexed: 11/25/2022]
Abstract
Although there has been an extensive research on vaccine development over the last decade and some vaccines have been commercialized for canine visceral leishmaniasis (CVL), but as yet no effective vaccine is available for anthroponotic VL which may partly be due to the absence of an appropriate adjuvant system. Vaccines alone yield poor immunity hence requiring an adjuvant which can boost the immunosuppressed state of VL infected individuals by eliciting adaptive immune responses to achieve required immunological enhancement. Recent studies have documented the continuous efforts that are being made in the field of adjuvants research in an attempt to render vaccines more effective. This review article focuses on adjuvants, particularly particulate and non-particulate ones, which have been assessed with VL vaccine candidates in several preclinical and clinical trials outlining the induction of immune responses obtained from these studies. Moreover, we have emphasized the applicability of multiple adjuvants combination for an improvement in the potential of a VL vaccine.
Collapse
Affiliation(s)
- Sneha Ratnapriya
- Molecular and Structural Biology Division, CSIR-Central Drug Research Institute, Sector-10, Jankipuram Extension, Sitapur Road, Lucknow 226031, India
| | - Keerti
- Molecular and Structural Biology Division, CSIR-Central Drug Research Institute, Sector-10, Jankipuram Extension, Sitapur Road, Lucknow 226031, India
| | - Amogh A Sahasrabuddhe
- Molecular and Structural Biology Division, CSIR-Central Drug Research Institute, Sector-10, Jankipuram Extension, Sitapur Road, Lucknow 226031, India
| | - Anuradha Dube
- Division of Parasitology, CSIR-Central Drug Research Institute, Sector-10, Jankipuram Extension, Sitapur Road, Lucknow 226031, India.
| |
Collapse
|
11
|
Dias DS, Ribeiro PA, Salles BC, Santos TT, Ramos FF, Lage DP, Costa LE, Portela AS, Carvalho GB, Chávez-Fumagalli MA, Caligiorne RB, Oliveira JS, Magalhães-Soares DF, Silva ES, Galdino AS, Menezes-Souza D, Duarte MC, Gonçalves DU, Coelho EA. Serological diagnosis and prognostic of tegumentary and visceral leishmaniasis using a conserved Leishmania hypothetical protein. Parasitol Int 2018; 67:344-350. [DOI: 10.1016/j.parint.2018.02.001] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2017] [Revised: 12/27/2017] [Accepted: 02/02/2018] [Indexed: 01/06/2023]
|